The National Institute for Health and Care Excellence has announced that it plans to recommend a technology that holds catheters in place and reduces infection risk for use by the NHS.
The draft medical technologies guidance proposes to recommend the use of the 3M Tegaderm CHG IV securement dressing for catheters inserted into central veins and arteries.
The dressing is a sterile transparent semipermeable polyurethane adhesive dressing, with an integrated gel pad containing the antibacterial agent chlorhexidine gluconate. It costs £6.21.
The draft guidance said the dressing should be considered for use in critically ill patients who required a central venous or arterial catheter in either intensive care or high dependency units.
“This transparent technology enables the catheter insertion site to be seen clearly”
The device manufacturer, 3M, has claimed that the benefits of the Tegaderm CHG dressing include a 60% reduction in the incidence of catheter-related bloodstream infection in critical care patients with intravascular catheters, and reduced risk of death from this type of infection.
Professor Carole Longson, director of the NICE centre for health technology evaluation, highlighted that bloodstream infections linked to central venous catheters increased both patient illness and costs for intensive care units.
“Using catheters in providing treatment or monitoring is a common procedure, and it’s important that they can be held in place securely whilst minimising infection risk to the patient,” she said.
She added: “The draft guidance notes that this transparent technology enables the catheter insertion site to be seen clearly, and also provides antiseptic coverage.
“For hospitals and units which have a moderate rate of baseline catheter-related bloodstream infection, this technology could save an estimated £73 per patient instead of using a standard transparent semipermeable dressing,” said Professor Longson.
The consultation closes on 17 April, with a final version of the guidance set to follow.